|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1850 K STREET, NW |
Address2 | SUITE 650 |
City | WASHINGTON |
State | DC |
Zip Code | 20006 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Cambridge |
State | MA |
Zip Code | 02142 |
Country | USA |
|
5. Senate ID# 16054-12
|
||||||||
|
6. House ID# 302570000
|
TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Mary McGrane, Senior Vice President |
Date | 04/17/2008 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S. 1145, Patent Reform Act of 2007
HR. 1908, Patent Reform Act of 2007
H.R. 1038, Access to Life-Saving Medicine Act, follow-on biologics
H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics
H.R. 5629, Pathway for Biosimilars Act
S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics
S. 1695, Biologics Price Competition and Innovation Act of 2007, Follow-on Biologics
S. 623, Access to Life-Saving Medicine Act, follow-on biologics
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mary |
McGrane |
|
Senior Vice President |
|
Sara |
Froelich |
|
Vice President |
|
Kay |
Holcombe |
|
Senior Policy Advisor |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 2606, 340B Program Improvement and Integrity Act of 2007, 340 B drug price expansion
H.R. 3162, Children's Health and Medicare Protection Act of 2007
H.R. 4, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provisions
H.R. 5480, Medicare Funding Warning Response Act of 2008
S. 1376, 340B Program Improvement and Integrity Act of 2007, 340 B Drug price expansion
S. 2029, Physician Payments Sunshine Act of 2007
S. 2662, Medicare Funding Warning Response Act of 2008
S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provision
Comparative Effectiveness
S. 2099 "Preserving Access to Laboratory Services Act of 2007"
Repeal of competitive bidding demo
Bundling payment system for dialysis centers
Medicare prescription drug benefit
H.R. 1321 "Medicare Advanced Laboratory Diagnostics Act of 2007"
S.2404 "The Medicare Advanced Laboratory Diagnostic Act of 2007"
S.691/H.R. 1193 The Kidney Care Quality and Education Act
CPT Coding decisions and HCPCS coding decisions
Reimbursement for Part B Drugs administered in hospital outpatient departments, dialysis centers and physician officers.
Physicians fee schedule payment rates for lab tests.
Medicaid rebates
H.R. 2184, the Enhanced Health Care Value for All Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS),
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mary |
McGrane |
|
Senior Vice President |
|
Sara |
Froelich |
|
Vice President |
|
Kay |
Holcombe |
|
Senior Policy Advisor |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H.R. 1038, Access to Life-Saving Medicine Act, follow-on biologics
H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics
H.R. 5629, Pathway for Biosimilars Act
S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics
S. 1695, Biologics Price Competition and Innovation Act of 2007, Follow-on Biologics
S. 2029, Physician Payments Sunshine Act of 2007
S. 623, Access to Life-Saving Medicine Act, follow-on biologics
Neglected Disease Issues
Issues related to Drug Safety, Generic Biologics & Drug Approvals
H.R. 380, "Pharmaceutical Market Access and Drug Safety act of 2007" - Importation.
S.251, Pharmaceutical Market Access & Drug Safety Act of 2007" - Importation.
S.242, "Pharmaceutical Market Access & Drug Safety Act of 2007"
H.R. 1561, Enhancing Drug Safety and Innovation Act of 2007
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mary |
McGrane |
|
Senior Vice President |
|
Sara |
Froelich |
|
Vice President |
|
Kay |
Holcombe |
|
Senior Policy Advisor |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
H.R. 3453, Community Clinical Laboratory Fairness in Competition Act of 2007
Reimbursement for clinical lab services under Medicare
H.R. 1321 "Medicare Advanced Laboratory Diagnostics Act"; S.2404 "The Medicare Advanced Laboratory Diagnostic Act of 2007"
S.976 "Genomics & Personalized Medicine Act of 2007"
Competitive bidding for lab tests
S.736, "The Laboratory Test Improvement Act"
17. House(s) of Congress and Federal agencies Check if None
Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mary |
McGrane |
|
Senior Vice President |
|
Sara |
Froelich |
|
Vice President |
|
Kay |
Holcombe |
|
Senior Policy Advisor |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |